dm+d
Unassigned
New Medicines
Moderate-to-severe plaque psoriasis
Information
New molecular entity
Can-Fite BioPharma
Can-Fite BioPharma
Development and Regulatory status
None
Phase III Clinical Trials
Phase III Clinical Trials
Category
Adenosine A3 receptor agonist inhibiting pro-inflammatory cytokines IL-17 and IL-23
Estimated UK prevalence of psoriasis is about 1.3 - 2.2%, plaque psoriasis accounting for 90% [2]. About 20% of patients have moderate to severe disease [3].
Moderate-to-severe plaque psoriasis
Oral
Rheumatoid arthritis (RA) - first-line
Information
New molecular entity
Can-Fite BioPharma
Can-Fite BioPharma
Development and Regulatory status
Discontinued
Discontinued
Discontinued
Nov 20Following the IDMC recommendation not to continue the PIII ACROBAT study, CanFite conducted a detailed analysis which showed that although piclidenoson efficacy was significantly superior to placebo, the study missed the primary endpoint (non-inferiority vs. the comparator methotrexate). CanFite therefore plan to focus on the developments that showed promising data including psoriasis and liver cancer [13].
Category
A3 adenosine receptor (A3AR) agonist
About 1 in 100 people develops RA at some stage in their life. RA develops at any age, but most commonly starts between the ages of 40 and 60. It is about three times more common in women than in men.
Rheumatoid arthritis (RA) - first-line
Oral